Innova Captab Ltd
Innova Captab Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Innova Captab aims for a long-term CAGR of 25% revenue growth over the next 3 years. Innova Captab aims for a 25% CAGR revenue growth over the next 3 years.
From Innova Captab Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Innova Captab aims for a long-term CAGR of 25% revenue growth over the next 3 years.
- Jammu plant is expected to contribute around INR 400 crores in revenue for FY '26, with initial revenue of INR 36 crores in Q4 FY '25.
- CDMO business volume growth is estimated around 7%-8% for the full year, slightly better than reported revenue growth of 6%-7%.
- Sharon business aims to revive and grow positively post-CIRP, focusing on onboarding new customers and products, targeting regulated markets like Europe and Canada.
- Domestic Branded Generics expect mid-teen growth rates (~12-13%), driven by volume growth, new products, and market penetration.
2 more points from Innova Captab Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Innova Captab Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innova Captab has commissioned a new facility in Kathua, Jammu, which started commercial operations in January 2025.
- The company expects the Jammu plant to generate around INR 400 crores in revenue in FY '26.
- Upcoming R&D facility in Panchkula, Haryana focused on developing generic and complex generic products, including immediate release, super bioavailability capsules, and nano size formulations targeting regulated markets.
- The Jammu plant includes expansion into acute products, beta-lactam, penem, LVP, respules, and waterfall injection formulations, reflecting strategic product portfolio diversification.
2 more points from Innova Captab Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Innova Captab Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The management did not explicitly mention a specific current or expected orderbook value during the call.
- Confidence was expressed regarding future revenue targets, including a guidance of INR 400 crores incremental revenue from the Jammu plant in FY '26.
- The company is maintaining a long-term revenue CAGR target of 25% over the next three years.
- Efforts are focused on onboarding new customers and products, especially in regulated markets like Europe and Canada through their Sharon subsidiary.
- The Jammu plant, recently commercialized, is expected to contribute significantly to revenue and margin improvement as operations scale.
2 more points from Innova Captab Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Innova Captab Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹448 Cr, net profit ₹38 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Innova Captab Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Innova Captab Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Innova Captab Ltd Q4 FY25 results?
Innova Captab aims for a long-term CAGR of 25% revenue growth over the next 3 years. Innova Captab aims for a 25% CAGR revenue growth over the next 3 years.
What is Innova Captab Ltd share price analysis?
Innova Captab Ltd currently shows a neutral. The stock trades at a P/E of 38.5 with a market cap of ₹5,408 Cr. Investors should review the full earnings analysis for detailed insights.
Is Innova Captab Ltd planning capital expenditure?
Innova Captab has commissioned a new facility in Kathua, Jammu, which started commercial operations in January 2025.
Keep Innova Captab Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.